BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
(d)Exhibits
|
ExhibitNo. |
Description of Exhibit |
| 2.1 | Amendment No. 1, dated July 28, 2017, to the Agreement and Plan of Merger, dated as of April23, 2017, among C. R. Bard, Inc., Becton, Dickinson and Company and Lambda Corp. |
4
BECTON DICKINSON & CO ExhibitEX-2.1 2 d399989dex21.htm EX-2.1 EX-2.1 Exhibit 2.1 EXECUTION VERSION AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This Amendment No. 1 (this “Amendment”) to the Agreement and Plan of Merger,…To view the full exhibit click here
About BECTON, DICKINSON AND COMPANY (NYSE:BDX)
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
